Table of Contents
MAPLE GROVE, Minn. — Upsher-Smith Laboratories, LLC (Upsher-Smith) announced the launch of Doxazosin tablets, USP, 1 mg, 2 mg, 4 mg and 8 mg.
The product was approved by the U.S. Food and Drug Administration (FDA) on April 17, 2018. Upsher-Smith’s Doxazosin t
ablets are an AB-rated generic version of the branded product, Cardura (doxazosin mesylate tablets).
The doxazosin tablet market had U.S. sales of approximately $51.2 million for the 12 months ending January, 2018 according to IQVIA.
